Louisiana 2022 Regular Session

Louisiana Senate Bill SB296

Introduced
3/3/22  
Refer
3/3/22  
Refer
3/3/22  
Refer
3/14/22  
Refer
3/14/22  
Report Pass
4/27/22  
Report Pass
4/27/22  

Caption

Provides relative to reimbursement for pharmacist clinical services in Louisiana's Medicaid program. (gov sig) (EG INCREASE GF EX See Note)

Impact

The enactment of SB 296 is expected to significantly influence the operational landscape for pharmacists in Louisiana, particularly regarding their role in patient care under the Medicaid program. By formalizing reimbursement processes, the bill aims to promote more comprehensive healthcare delivery through pharmacists, potentially leading to improved patient outcomes. This change could facilitate increased accessibility to clinical services for Medicaid recipients, especially in underserved areas, as pharmacists often serve as frontline healthcare providers.

Summary

Senate Bill 296 aims to enhance the reimbursement framework for pharmacist clinical services within Louisiana's Medicaid program. It defines pharmacist clinical services as patient care delivered by licensed pharmacists, targeting improvements in managing diseases and medical conditions. The bill stipulates that for pharmacists to receive Medicaid reimbursement, they must adhere to certain qualifications and requirements set by the Louisiana Department of Health (LDH), which includes having a National Provider Identification number and fulfilling Medicaid’s clinical service guidelines.

Sentiment

The general sentiment surrounding SB 296 appears favorable among healthcare advocates who believe that greater utilization of pharmacists will enhance patient care in the state. Supporters argue that by recognizing pharmacists as integral to the healthcare team, the bill could alleviate pressure on other healthcare providers and improve health outcomes. However, there also exists some skepticism about the bill's implementation and the adequacy of regulations to prevent fraud and ensure service quality.

Contention

Notable points of contention regarding SB 296 include concerns from some stakeholders about the potential for overreach by the state health department in regulating pharmacist practices. Some legislators worry that the provisions could lead to complexities in managing compliance and reimbursement processes. Additionally, there are apprehensions about ensuring adequate oversight to prevent any substantial fraud in billing for these services, particularly as the landscape for telehealth expands.

Companion Bills

No companion bills found.

Similar Bills

LA HB1180

Provides for a feasibility study concerning a pharmaceutical and therapeutics committee for Medicaid managed care

LA SB117

Provides for the Medicaid Pharmaceutical and Therapeutics Committee.

LA SB83

Creates the Council on Medicaid Pharmacy Reimbursement. (8/1/22) (EN NO IMPACT See Note)

RI S2617

Adds a new section which sets forth conditions for pharmacists to prescribe tobacco cessation/drug therapies, programs approved by the state board of pharmacy. The cessation therapies would be covered by all health insurance carriers on or after 1/1/25.

RI H7445

Adds a new section which sets forth conditions for pharmacists to prescribe tobacco cessation/drug therapies, programs approved by the state board of pharmacy. The cessation therapies would be covered by all health insurance carriers on or after 1/1/25.

LA HCR88

Urges and requests the La. Department of Health to utilize increased collections from pharmacy rebates to increase rates for primary care providers in the Medicaid program

LA HB393

Provides relative to prescription drug benefits of certain managed care organizations participating in the La. Medicaid coordinated care network program (RE1 INCREASE GF EX See Note)

CA SB159

HIV: preexposure and postexposure prophylaxis.